Peroxisome proliferator-activated receptors (PPARs) act as metabolic sensors and central regulators of fat and glucose homeostasis 1 . Furthermore, PPARg has been implicated as major catabolic regulator of bone mass in mice and humans [2] [3] [4] [5] . However, a potential involvement of other PPAR subtypes in the regulation of bone homeostasis has remained elusive. Here we report a previously unrecognized role of PPARb/d as a key regulator of bone turnover and the crosstalk between osteoblasts and osteoclasts. In contrast to activation of PPARg, activation of PPARb/d amplified Wnt-dependent and b-catenin-dependent signaling and gene expression in osteoblasts, resulting in increased expression of osteoprotegerin (OPG) and attenuation of osteoblast-mediated osteoclastogenesis. Accordingly, PPARb/d-deficient mice had lower Wnt signaling activity, lower serum concentrations of OPG, higher numbers of osteoclasts and osteopenia. Pharmacological activation of PPARb/d in a mouse model of postmenopausal osteoporosis led to normalization of the altered ratio of tumor necrosis factor superfamily, member 11 (RANKL, also called TNFSF11) to OPG, a rebalancing of bone turnover and the restoration of normal bone density. Our findings identify PPARb/d as a promising target for an alternative approach in the treatment of osteoporosis and related diseases.
Peroxisome proliferator-activated receptors (PPARs) act as metabolic sensors and central regulators of fat and glucose homeostasis 1 . Furthermore, PPARg has been implicated as major catabolic regulator of bone mass in mice and humans [2] [3] [4] [5] . However, a potential involvement of other PPAR subtypes in the regulation of bone homeostasis has remained elusive. Here we report a previously unrecognized role of PPARb/d as a key regulator of bone turnover and the crosstalk between osteoblasts and osteoclasts. In contrast to activation of PPARg, activation of PPARb/d amplified Wnt-dependent and b-catenin-dependent signaling and gene expression in osteoblasts, resulting in increased expression of osteoprotegerin (OPG) and attenuation of osteoblast-mediated osteoclastogenesis. Accordingly, PPARb/d-deficient mice had lower Wnt signaling activity, lower serum concentrations of OPG, higher numbers of osteoclasts and osteopenia. Pharmacological activation of PPARb/d in a mouse model of postmenopausal osteoporosis led to normalization of the altered ratio of tumor necrosis factor superfamily, member 11 (RANKL, also called TNFSF11) to OPG, a rebalancing of bone turnover and the restoration of normal bone density. Our findings identify PPARb/d as a promising target for an alternative approach in the treatment of osteoporosis and related diseases.
Long-term usage of PPARγ agonists such as rosiglitazone increases fracture rates and the risk of osteoporosis [2] [3] [4] [5] . Mechanistically, activation of PPARγ suppresses the differentiation of bone-forming osteoblasts 2, 6 and simultaneously promotes the differentiation of bone-resorbing osteoclasts 7, 8 , resulting in a net loss in bone mass. These effects can be attributed to a reciprocal inhibition of PPARγ and Wnt signaling in mesenchymal stem cells (MSCs) and osteoblast precursors 2, [9] [10] [11] [12] . In these cells, activation of the low density lipoprotein receptor-related protein 5 (LRP5)-frizzled Wnt receptor complex by Wnt proteins triggers accumulation and nuclear translocation of β-catenin, which results in T cell factor/lymphoid enhancer factor (TCF/LEF)-dependent transcriptional activity and increased differentiation of bone-forming osteoblasts 9, 13 . Simultaneously, Wnt signaling induces the expression of OPG, suppressing osteoclast development and additionally increasing bone mass [13] [14] [15] [16] .
Similarly to PPARγ, PPARβ/δ regulates lipid metabolism and energy homeostasis. However, PPARγ and PPARβ/δ promote divergent metabolic programs 1 . Wnt signaling activity has also been shown to silence expression of PPARγ 12 , whereas it simultaneously induces expression of PPARβ/δ 17, 18 , indicating distinct roles of these two PPAR subtypes in the regulation of Wnt-dependent processes.
Among the three PPAR isotypes, differentiated primary osteoblasts expressed predominantly Ppard mRNA (Fig. 1a) . Notably, activation of PPARβ/δ by the specific agonist GW501516 resulted in the accumulation of nuclear β-catenin in both osteoblasts and MSCs, whereas activation of PPARγ by rosiglitazone did not (Fig. 1b) . GW501516 additionally amplified the Wnt ligand-induced increase in nuclear β-catenin accumulation. Similarly, activation of PPARβ/δ (but not PPARγ) induced the Wnt-dependent mRNA expression of osteoblast marker genes encoding for OPG (Tnfrsf11b), osterix (Sp7) and Runx2 (Runx2) in osteoblasts and C3H10T1/2 mesenchymal cells ( Fig. 1c and Supplementary Fig. 1a ) and markedly augmented Sp7 mRNA expression in MSCs (Fig. 1c) . However, these effects were dependent on the presence of canonical Wnt ligands such as Wnt3a or Wnt10b.
To elucidate the synergy between PPARβ/δ and Wnt signaling, we performed an in silico analysis of promoter regions of genes involved in Wnt signaling. We identified multiple PPAR-responsive elements in the promoter of the gene encoding for the Wnt co-receptor LRP5, rendering it a potential PPAR target gene. Indeed, GW501516 induced LRP5 mRNA and protein expression (Fig. 1d,e) , and the induction of β-catenin followed a similar kinetic (Fig. 1f) . Chromatin immunoprecipitation (ChIP) experiments showed direct binding of PPARβ/δ to the Lrp5 promoter in osteoblastic MC3T3 cells (Fig. 1g) . The subsequent analysis of a 1.6-kb mouse Lrp5 promoter-driven luciferase reporter confirmed the regulation by PPARβ/δ and its ligand.
GW501516 induced activity of the Lrp5 promoter in the presence of its receptor, whereas expression of non-ligand bound PPARβ/δ decreased promoter activity (Fig. 1h) . As Ppard was previously identified as a Wnt target gene 17, 18 , these findings indicate a positive feedback loop between both pathways (Supplementary Fig. 1b) .
As nuclear β-catenin has been shown to interact directly with different nuclear receptors 10 , we addressed the possibility of a direct synergistic interaction between PPARβ/δ and nuclear β-catenin. Coimmunoprecipitation experiments showed formation of complexes between the proteins after induction of Wnt signaling (Fig. 1i) . Furthermore, PPARβ/δ directly promoted TCF-induced transcriptional activity (Fig. 1j) . We concluded that activation of PPARβ/δ amplified Wnt signaling activity and TCF-dependent transcription in osteoblasts and MSCs through (at least) two mechanisms, including transcriptional regulation of Lrp5 and direct interaction with β-catenin (Supplementary Fig. 1b ).
Wnt signaling has been shown to promote osteoblast differentiation and simultaneously interferes with osteoblast-mediated osteoclastogenesis 13 . Indeed, activation of PPARβ/δ promoted the osteogenic differentiation of osteoblasts in terms of bone nodule formation and alkaline phosphatase expression (Fig. 2a,b) . In cocultures of osteoblasts and osteoclasts, the PPARβ/δ agonist induced expression of OPG and decreased the RANKL-to-OPG ratio (Fig. 2c) . This was paralleled by an inhibition of osteoclast differentiation and bone resorption (Fig. 2d,e) . Again, the effects of GW501516 and canonical Wnt ligands were additive ( Fig. 2d and Supplementary Fig. 2a) . We confirmed the functional ties between PPARβ/δ and Wnt signaling by siRNA-mediated silencing of PPARβ/δ or of the Wnt co-receptor LRP5 in osteoblasts, both of which abrogated the inhibitory effect of GW501516 on osteoclastogenesis in cocultures of osteoblasts and osteoclasts (Fig. 2f,g ). To determine the contribution of OPG to the observed effects, we added recombinant RANKL to the coculture, which resulted in the abrogation of the PPARβ/δ-and Wnt-mediated inhibition (Fig. 2h) . Notably, activation of PPARβ/δ did not directly affect osteoclastogenesis, as the PPARβ/δ agonist no longer blocked osteoclast differentiation or bone resorption when osteoclasts were generated in the absence of osteoblasts (Fig. 2i,j) . Deletion of the gene encoding for PPARβ/δ (Ppard) results in embryonic lethality of Ppard −/− mice due to placental insufficiency 19 . To study the role of PPARβ/δ during bone homeostasis in vivo, we analyzed mice carrying a conditional deletion of Ppard in all tissues except the placenta using a Sox2-Cre system (Ppard Sox2-cKO mice) 20 . Ppard Sox2-cKO mice showed substantial osteopenia in the long and vertebral bones (Fig. 3a,b) . In accordance with a role of PPARβ/δ during the regulation of Wnt signaling in vivo, bone-lining osteoblasts of Ppard Sox2-cKO mice showed lower expression of β-catenin than osteoblasts of their wild-type (Ppard flox/+ ) littermates (Fig. 3c) . Furthermore, Ppard Sox2-cKO mice had lower serum concentrations of OPG and osteocalcin as well as a higher RANKL-to-OPG ratio compared to their wild-type littermates (Fig. 3d) . These changes were paralleled by higher numbers of osteoclasts within the trabecular bones of Ppard Sox2-cKO compared to Ppard flox/+ mice ( Fig. 3e and Supplementary Table 1 ). The number of osteoblasts and the mineral apposition rate were not altered between these groups (Fig. 3f,g and Supplementary Table 1) .
Because these data confirmed a crucial role of PPARβ/δ during bone homeostasis, we evaluated the therapeutic potential of pharmacological activation of PPARβ/δ in the treatment of pathologic bone loss. We used an ovariectomy (OVX)-induced model of postmenopausal osteoporosis in which we performed OVX in mice at 12 weeks of age and treated them with GW501516 starting 4 weeks later (after the onset of osteoporosis). Six weeks of treatment with GW501516 restored normal bone morphology and bone density of tibial and vertebral bone (Fig. 4a,b) . We found a reversal of the OVX-induced alterations in Wnt signaling in bone-lining osteoblasts, a normalization of serum osteocalcin concentrations, a rebalancing of the RANKLto-OPG ratio (Fig. 4c,d ) and restoration of the physiologic osteoclast content ( Fig. 4e and Supplementary Table 1) . Furthermore, our analyses showed a GW501516-induced increase in the number of osteoblasts and mineral apposition rate of ovariectomized mice (Fig. 4f,g and Supplementary Table 1) . However, we found that GW501516 had only a small effect on bone homeostasis in nonovariectomized mice ( Supplementary Fig. 3a-f and Supplementary Table 1) . Our data reveal a role for PPARβ/δ as key regulator of Wnt signaling and systemic bone turnover. In osteoblasts and MSCs, activation of this nuclear receptor promoted Wnt signaling through direct interaction with β-catenin and regulation of Lrp5, a gene previously identified as major factor determining systemic bone mass 13, 21 . PPARβ/δ also controlled the RANKL-to-OPG ratio and thereby influenced the rate of osteoclastogenesis. In vivo, this regulation of Wnt signaling and OPG expression might involve osteoblasts, MSCs and osteocytes, cell types that all contribute to bone homeostasis. However, neither PPARβ/δ ligands nor PPARβ/δ deficiency ( Supplementary Fig. 4 ) directly affected osteoclast differentiation or function. Although different putative PPAR ligands were previously reported to exert direct anti-osteoclastogenic effects in vitro 22, 23 , such findings are probably caused by nonspecific actions of high concentrations of PPAR agonists.
So far, PPARβ/δ has been implicated mainly as a regulator of energy metabolism in adipose tissue and muscle, where it acts as a sensor for metabolic substrates in the form of fatty acids and enhances thermogenesis and fatty acid catabolism 24 . Furthermore, PPARβ/δ improves muscular endurance by inducing changes in the composition of myofibers 25 . As the skeleton itself has recently emerged as an important factor in the regulation of energy homeostasis 26 , PPARβ/δ expression in osteoblasts could potentially contribute to the beneficial metabolic effects exerted by this receptor. Our current data indicate that the molecular crosstalk between PPARβ/δ and Wnt signaling allows for an increase in the supply of energy substrates to translate into an increase in bone mass.
Notably, GW501516 had little impact on Wnt signaling and bone turnover during the steady state, whereas it markedly induced β-catenin accumulation and bone formation after OVX. Hence, OVXrelated estrogen deprivation seems to directly or indirectly affect PPARβ/δ activity in osteoblasts, which might be related to changes in the activation status of the osteoblast or may potentially involve a crosstalk between the estrogen receptor and PPARβ/δ-induced signaling. In analogy, the anabolic effects of GW501516 on skeletal muscle require the combination of drug treatment and exercise 24 . This indicates that activation of PPARβ/δ exerts context-dependent biological effects, which rely on a second signal, including the activation of certain cofactors such as AMP-activated protein kinase (AMPK) 24, 25 , during states of exercise and high bone turnover.
Because activation of PPARγ by insulin-sensitizing thiazolidinediones causes osteopenia in mice and humans 2, 5 , our current data show that PPARβ/δ and PPARγ act in an antagonistic manner during bone turnover. The nonspecific PPARα and PPARβ/δ pan agonists linoleic acid and bezafibrate were previously shown to promote the differentiation of osteoblasts in vitro and induce periosteal bone formation in vivo, indicating a potential role of PPARα during npg bone homeostasis 27 . However, this previous study focused only on the steady state, where the authors observed no effect on osteoclast numbers or trabecular bone.
In contrast to most of the current osteoporosis treatment strategies, activation of PPARβ/δ seems to protect from pathologic bone loss by balancing the RANKL-to-OPG ratio and restoring bone homeostasis rather than merely blocking osteoclast differentiation or function. As pharmacological PPARβ/δ agonists have entered the stage of clinical trials as lipid-lowering drugs 28 , our findings open potential new therapeutic avenues for the treatment of osteoporosis and related diseases.
MeTHOdS
Methods and any associated references are available in the online version of the paper. OVX. We obtained female C57BL/6 mice from Charles River. For OVX experiments, mice (12 weeks of age) were bilaterally ovariectomized, and the ovaries of the sham group were left intact. Both sets of mice were kept in identical housing conditions controlling for the same environment, food, light and temperature conditions. The ovariectomized mice recovered for 4 weeks to ensure the development of osteoporosis. We fed the PPARβ/δ-specific agonist GW501516 (10 mg per kg body weight per d in 150 µl 0.5% carboxymethylcellulose (CMC)) or vehicle to the mice in each group on a daily base. For analysis, all mice were killed after 6 weeks of treatment at the age of 22 weeks.
We performed a histological analysis of the surgically removed ovaries to verify OVX. To confirm onset of osteoporosis, we analyzed microcomputer tomography (µCT) images of tibias of mice at an age of 16 weeks (4 weeks after ovariectomy) (data not shown).
Bone analyses. We measured the structure of tibial and vertebral bones with a SCANCO Medical µCT 40 scanner to produce the images and analyzed them with SCANCO evaluation software for segmentation, three-dimensional morphometric analysis, density and distance parameters (SCANCO Medical AG).
We performed histomorphometric analyses with the Osteomeasure Analysis System (Osteometrics) to determine osteoclast and osteoblast parameters as previously described 30 . For assessment of bone formation, we injected green fluorescent calcein (Sigma; 5 mg per kg body weight) into the mice on days 7 and 2 before killing.
ELISA.
We determined serum concentrations of RANKL and OPG (R&D Systems), as well as osteocalcin (Biomedical Technologies, Inc.), according to the instructions in the manufacturer's protocol.
Immunohistochemistry.
We performed the analysis of β-catenin expression in osteoblasts of tibial bones using a polyclonal antibody to β-catenin (#sc-7199, Santa Cruz, dilution 1:200) as previously described 31 .
Cell culture. Differentiation of bone marrow-derived osteoclasts and isolation of calvarial osteoblasts was previously described 30 . After 4-6 d of culture, we performed TRAP staining for the evaluation of osteoclast differentiation using a leukocyte acid phosphatase kit (Sigma) and identified osteoclasts as TRAP-stained cells with three or more nuclei. Experiments using cocultures of osteoblasts and osteoclasts were performed as previously described 30 . Briefly, we cocultured primary osteoblasts (5 × 10 4 per well) with bone marrow cells (1 × 10 6 per well) in the presence of 10% FCS, 1,25(OH)2D3 (10 −8 M) and dexamethasone (10 −7 M) in 24-well plates and performed TRAP staining for the evaluation of osteoclast differentiation after 8-10 d of culture. For osteoclast monocultures, we differentiated bone marrow cells in the presence of RANKL (10 ng ml −1 ) and macrophage colony-stimulating factor (MCSF) (30 ng ml −1 ) as previously described 30 . MSCs were isolated and fully characterized from C57BL/6 mice as described previously 32 following the mesenchymal stem cell minimal criteria 33 . Briefly, we flushed bone marrow out of long bones and plated the cell suspension (0.5 × 10 6 cells cm −2 ) in α-MEM (Life Technologies) supplemented with 10% FBS (Hyclone, Thermo Fisher Scientific), 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (Lonza) and 2 ng/ml human basic fibroblast growth factor (bFGF) (R&D Systems). At subconfluence, we plated cells at a density of 5,000 cells cm −2 and used cells between passages 7 and 12. We also tested the capacity of MSCs to differentiate toward the chondrogenic, adipogenic and osteogenic lineages.
Recombinant proteins. We collected Wnt3a-conditioned medium from L cells stably transfected with Wnt3a (ATCC number CRL-2647) as proposed by ATCC. Mouse Wnt10b was obtained from R&D Systems (#2110).
Mineralization assay. We performed mineralization assays as previously described in the presence of ascorbic acid and β-glycerol phosphate 30 and quantified bone nodules and mineralized area using an Osteomeasure Analysis System (Osteometrics).
Resorption assay. We plated osteoclasts in the presence and absence of calvarial osteoblasts into 96-well plates previously equipped with bone slices (IDS Immunodiagnostic Systems). Cells were cultured in the appropriate medium for at least 10 d. We visualized resorption pit formation by toluidine blue (1%) staining after removal of cells by ultrasonication (in 70% isopropanol for 15 min.). We then quantified resorption pits and resorption area using an Osteomeasure Analysis System (Osteometrics). Quantification was determined by toluidine blue staining of osteoclast resorption area per total area.
siRNA transfection. We grew cells to 70% confluence in complete growth medium without antibiotics and then performed transfections using Lipofectamine RNAiMAX (Invitrogen) with a Ppard-specific siRNA (Ppard Stealth Select RNAi, Invitrogen), an Lrp5-specific siRNA (Lrp5 Stealth Select RNAi, Invitrogen) or a negative control siRNA (Stealth RNAi Negative Control Duplexes, Invitrogen). After 6 h, we changed the transfection medium and stimulated cells with the appropriate cytokines and GW501516. Transfection efficiency was assessed using Block-it Alexa Flour Oligo (Invitrogen, Karlsruhe, Germany) as a positive control. Ppard and Lrp5 gene knockdown was confirmed by real-time PCR analysis.
Nuclear extracts. Cells were washed and scraped in ice-cold PBS after centrifugation. We resuspended pellets in a hypotonic buffer and incubated them for 20 min on ice. After cell-membrane lysis, the pellet of the nuclear extracts was dissolved in Laemmli buffer and analyzed by western blotting.
Western blotting. We washed cultured cells twice with PBS and then lysed them. Protein extracts were fractionated by SDS-PAGE and transferred to a Trans-Blot Nitrocellulose membrane (BioRad). After blocking with 5% nonfat dry milk in Tris-buffered saline (TBS), we incubated the membranes overnight at 4 °C with antibody to β-catenin (#C2206, Sigma-Aldrich, dilution 1:2,000) and antibody to LRP5 (#ab38311, Abcam, dilution 1:500). For loading control, we used antibodies to β-actin (clone AC-74, Sigma-Aldrich, dilution 1:1,000) and lamin A/C (#2032, Cell Signaling, dilution 1:1,000).
Real-time PCR analysis. We isolated total RNA from cells by using peqGOLD TRIFast (peqlab) and used 1 µg RNA for first-strand complementary DNA synthesis (Amersham Biosciences). We then performed SYBR Green-based quantitative real-time PCR as previously described 34 . We quantified target gene expression using a mathematical model by Pfaffl et al. 35 . The following real-time PCR primer sequences were used: Tnfrsf11b, 5′-AGCTGCTGAAGCTGTGG AA-3′ (sense) and 5′-GGTTCGAGTGGCCGAGAT-3′ (antisense); Runx2, 5′-GA CGAGGCAAGAGTTTCACC-3′ (sense) and 5′-GGACCGTCCACTGTC ACTTT-3′ (antisense); Sp7, 5′-GGAGGCACAAAGAAGCCATACGC-3′ (sense) and 5′-TGCAGGAGAGAGGAGTCCATTG-3′ (antisense); Lrp5, 5′-TGGGCAAGAACCTCTATTGG-3′ (sense) and 5′-GGGTTGTCAAGGT CTCTCCA-3′ (antisense); Ppara, 5′-GGACCTTCGGCAGCTGGT-3′ (sense) and 5′-TCGGACTCGGTCTTCTTGATG-3′; Ppard, 5′-CTGAAGGGAAG GGGGTAGAG-3′ (sense) and 5′-CAGTCTGGATGCTGCTACA-3′ (antisense); and Pparg, 5′-CATTCTGGCCCACCAACTTC-3′ (sense) and 5′-TCAAAGGAATGCGAGTGGTCTT-3′ (antisense). Normalized gene expression values for each sample were calculated as the ratio of expression of mRNA of the gene of interest to the expression of mRNA for β-actin.
Promoter reporter analyses. We co-transfected HEK293 cells, which stably express a luciferase TCF reporter construct and a SV40-driven Renilla luciferase control plasmid, with 1 µg expression plasmids for PPARβ or a npg
